4/A: Inhibikase Therapeutics Director Corrects Beneficial Ownership in Form 4/A Filing

Dennis Berman, a director at Inhibikase Therapeutics, files an amended Form 4 to correct the reported beneficial owner of stock options.

Summary

• Dennis Berman, a director of Inhibikase Therapeutics, Inc. [IKT], filed an amended Form 4/A with the SEC on February 19, 2025.
• The amendment corrects an error in the original Form 4 filed on January 22, 2025, which incorrectly reported Molino Ventures, LLC as the beneficial owner of certain stock options.
• The corrected form identifies Dennis Berman as the direct beneficial owner of the stock options.
• The reported transactions reflect an option repricing effective January 21, 2025, approved by the Board of Directors on October 9, 2024, and stockholders on January 3, 2025.
• The repricing involved multiple stock option grants with an exercise price of $1.26, vesting at various dates between August 31, 2026, and July 16, 2031.
• The number of shares and exercise price have been adjusted to reflect a one-for-six reverse stock split effected on June 30, 2023.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a previous error, indicating a commitment to transparency. The option repricing suggests an effort to incentivize management, which is generally viewed positively.

Positives

• The company is transparently correcting an error in a previous filing.
• The option repricing was approved by both the Board of Directors and stockholders.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency and compliance with SEC regulations.

Stakeholder Impact

• Shareholders benefit from accurate and transparent reporting of insider transactions.

Key Dates

Keywords

Form 4/A, Inhibikase Therapeutics, Dennis Berman, Beneficial Ownership, Stock Options, Repricing, Director